| Locatelli, Eduardo |
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04 |
|
|
| Available | N/A | | US | CNM-Au8 | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) | ALS, Amyotrophic Lateral Sclerosis, PALS | | | | |
| No Longer Available | N/A | | US | Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL | Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
NCT06012110: Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis |
|
|
| Completed | N/A | 6 | US | Transcutaneous electrical stimulation | Nova Southeastern University | Primary Lateral Sclerosis | 08/24 | 08/24 | | |
| Schmidt, Emma |
| Recruiting | 3 | 150 | Europe, Canada, Japan, US, RoW | Tofersen, BIIB067, QALSODY, Placebo | Biogen | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | 08/27 | 08/27 | | |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
| Active, not recruiting | 2 | 40 | US, RoW | Fasudil (WP-0512) | Woolsey Pharmaceuticals | Amyotrophic Lateral Sclerosis | 07/26 | 01/28 | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Recruiting | N/A | 90 | US | Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification | University of Minnesota, Food and Drug Administration (FDA), Minnesota Office of Higher Education | Amyotrophic Lateral Sclerosis, ALS | 08/27 | 08/28 | | |
TALS LB, NCT05137665: Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures |
|
|
| Recruiting | N/A | 1000 | US, RoW | | Target ALS Foundation, Inc. | Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease | 12/31 | 12/31 | | |
| Recruiting | N/A | 5000 | Europe, US | | Massachusetts General Hospital, Henry Ford Health System, Northwestern University, Temple University, St. Louis University, University of Florida, University of Minnesota, Virginia Commonwealth University, Fondazione Serena Onlus - Centro Clinico NeMO Milano, Providence Health & Services, University of Pittsburgh, Istituti Clinici Scientifici Maugeri SpA | ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy | 12/30 | 12/30 | | |
